Endocrinology/Hormones

<p>SQ 31844 is a representative of the imidazole alcohols-a novel class of renin inhibitors.</p>

<p>Azetirelin, as a TRH analog, has a more potent effect than TRH on the central nervous system.</p>

<p>SB-568849 is a melanin-concentrating hormone receptor 1 antagonist (pKi: 7.7).</p>

<p>LY 43578 is an orally active aromatase inhibitor.</p>

<p>FSHR agonist 1: high-affinity, allosteric FSHR activator, pEC50 of 7.72, interacts with TMD.</p>

<p>MK319 is an AKR1B10 inhibitor.</p>

<p>CP-866087 is a novel, potent and selective mu-opioid receptor antagonist for the study of female sexual dysfunction.</p>

<p>urotensin-II (UT) receptor antagonist</p>

<p>ATC0065 dihydrochloride is a novel nonpeptidic and potent melanin-concentrating hormone receptor 1 (MCHR1) selective antagonist.</p>

<p>GPR84 antagonist 8 is a selective GPR84 antagonist applicable for investigating inflammatory and fibrotic diseases.</p>

<p>Camizestrant (Estrogen receptor antagonist 2) is an antagonist of the estrogen receptor and can be used in studies about ER+ HER2-advanced breast cancer[1].</p>

<p>L 158338 is an antagonist of the angiotensin receptor.</p>

<p>ERRγ Inverse Agonist 1 (Compound 12) is a potent, selective and orally bioavailable Estrogen-related Receptor grammar (ERRγ) inverse agonist (IC 50=40 nM) [1].</p>

<p>agonist at ERα receptor and antagonist at ERβ receptor</p>

<p>LY285434 is a suitable angiotensin II receptor antagonist.</p>

<p>Chlorothalonil (DAC 2787): Broad-spectrum, efficient, low-toxicity fungicide for fruits, vegetables, rice, wheat, cotton.</p>

<p>RU 58642 is an effective systemic antiandrogen for androgen-dependent disorders.</p>

<p>ERβ receptor agonist</p>

<p>ASN06917370 (Compound V) is a specific modulator of the orphan receptor GPR17 (Uracil Nucleotide/Cysteinyl Leukotriene Receptor), neuroprotective</p>

<p>SCH 221510: oral NOP agonist, EC50=12 nM, Ki=0.3 nM, anxiolytic, for neurological research.</p>

<p>Loperamide oxide (R 58425) is a secreted antidiarrheal agent that increases peristalsis and inhibits intestinal absorption of water and ions.</p>

<p>ADL-5747 (ADL-5747 (free base)) (free base) is a delta opioid receptor agonist used in the treatment of neurological disorders, skin and musculoskeletal</p>

<p>Ralaniten triacetate (EPI-506) is a precursor of Ralaniten, an AR-NTD inhibitor, which can be used in the study of prostate and breast cancer.</p>

<p>Buloxibutid: a novel AT2 receptor agonist, Ki=0.4 nM (AT2), 10 μM (AT1).</p>

<p>L-162,313 is an ANG II receptor agonist, a nonpeptide that mimics the biological actions of angiotensin II and induces an increase in MAP.</p>

<p>CRTh2 antagonist 2 is a selective and potent CRTH2 antagonist, IC50≤10 nM. CRTh2 antagonist 2 can be used to study the direction of androgenic alopecia.</p>

<p>MEDICA16: GPR40 agonist, GPR120 partial agonist, ATP-citrate lyase inhibitor, lowers TG, boosts insulin sensitivity in muscle.</p>

<p>Palazestrant, an antiestrogen and antineoplastic agent, effectively targets ER+/HER2+ cancer when used in conjunction with a HER2 inhibitor.</p>

<p>ICI 204,448 is a potent κ-opioid agonist with potential analgesic activity for the study of neurological diseases.</p>

<p>GPR35 agonist 2 (TC-G 1001) is a potent GPR35 agonist.The EC50 values of GPR35 agonist 2 in the β-arrestin and Ca2+ release assays were 26 and 3.2 nM,</p>

<p>Estredox, an estrogen receptor agonist, is used potentially for the treatment of vasomotor symptoms.</p>

<p>Glucocorticoid receptor agonist-1 is a potent glucocorticoid receptor agonist with an IC50 of 2.8 nM[1].</p>

<p>NNC 63-0532 is a potentnociceptin receptor agonist, Ki=7.3 nM, EC50=305 nM.</p>

<p>Finrozole (MPV 2213ad) is a novel selective aromatase inhibitor that is partially reversible for breast development.</p>

<p>Fezagepras sodium (Setogepram sodium salt) is an orally active GPR40 agonist and is an antagonist or inverse agonist for GPR84, with anti-fibrotic, anti-</p>

<p>Trimebutine CTB salt (GIC-1001) is an opioid receptor agonist used in the study of pain.</p>

<p>Bevenopran (CB-5945) is a peripheral antagonist of μ-opioid receptor and can be used in studies about the treatment of opioid-induced bowel dysfunction.</p>

<p>BMS-641988 is a novel nonsteroidal androgen receptor antagonist for the treatment of prostate cancer.</p>

<p>FPL-62129 is a calcium channel antagonist and a novel angiotensin-converting enzyme inhibitor with vasodilator activity for the study of cardiovascular disease.</p>

<p>GR 89696 fumarate is a highly selective κ2 opioid receptor agonist (IC50 = 0.04nM) with anti-pruritchy, anti-injury and neuroprotective effects.</p>

<p>LY2881835 is a potent and selective GPR40 agonist.</p>

<p>Ripisartan (UP-269-6) is a potent and specific angiotensin II receptor antagonist that inhibits angiotensin II-mediated sympathetic tachycardia responses.</p>

<p>CAY10786 (GPR52 antagonist-1) is an antagonist of G protein-coupled receptor 52 (GPR52, IC50 = 0.63 μM).</p>

<p>Zindoxifene (D 16726) is an anti-estrogenic compound with antitumor activity that can be used in studies of breast and prostate cancer.</p>

<p>LY88074, a raloxifene analog sans basic side chain, is an ERβ agonist (EC50 = 232 nM) that promotes uterine cell growth.</p>

<p>Estrogen Receptor Antagonist 8 is an ER antagonist with anti-uterine activity and may be used in the study of ovarian dysfunction.CASNETIN SODIUM (CasN)</p>

<p>Orotirelin (CG 3509), a TRH analog, counters pentobarbital sleep; may aid in cerebral ischemia.</p>

<p>FL104 is a potent agonist of small-molecule urotensin II receptor, pEC50= 7.11.</p>

<p>Lorundrostat is an aldosterone synthase inhibitor.</p>

<p>YL-365 is a highly potent and selective GPR34 antagonist that exhibits excellent activity in neuropathic pain models for the study of neurologic diseases.</p>

<p>Palatrigine (BW-A 256C) is a compound with angiotensin-converting enzyme inhibitory and beta-adrenergic receptor blocking properties.</p>

<p>MK 1903 is a strong, selective HCA2/GPR109A agonist, reducing cAMP in CHO cells with EC50 of 12.9 nM.</p>

<p>G36 is a cell-permeable non-steroidal antagonist of GPER.</p>

<p>ATC 0175 hydrochloride is an orally active melanocyte concentrating hormone 1 receptor antagonist that is potent and selective.</p>

<p>ML-335, a μ-δ targeted agonist and MOR/DOR ligand, may lead to isomer-biased drugs with pain-relief properties.</p>

<p>ZD-6888 Hydrochloride, an angiotensin type 1 receptor antagonist, is used potentially for the treatment of hypertension.</p>

<p>AMG-009 is a prostaglandin D2 antagonist. For CRTH2 and DP receptors, the IC50s are 3 nM and 12 nM, respectively.</p>

<p>ONC1-13B, an androgen receptor antagonist, is used potentially for the treatment of prostate cancer.</p>

<p>Cymit Quimica provides this product solely for uses within the scope of any statute or law providing for an immunity, exemption, or exception to patent infringement (“Exempted Uses”), including but not limited to 35 U.S.C. § 271(e)(1) in the United States, the Bolar type exemption in Europe, and any corresponding exception to patent infringement in any other country. It is the sole responsibility of the purchaser or user of this product, and the purchaser or user of this product agrees to engage only in such Exempted Uses, and to comply with all applicable intellectual property laws and/or regulations. The purchaser of this product agrees to indemnify Cymit Quimica against all claims in connection with the performance of the respective commercial agreement (e.g. supply agreement) and possible infringements of intellectual property rights.</p>

<p>LP-471756 is a specific antagonist of GPR139 and inhibits LP-360924-stimulated cAMP production (IC50 = 640 nM).</p>

<p>Terlakiren (CP-80,794) is a renin inhibitor that inhibits the potency of human renin and can be used to study neurological disorders of the hypertensive type.</p>

<p>GLPG1205 is a potent, orally active GPR84 (G protein-coupled receptor) antagonist with anti-inflammatory activity.</p>

<p>Faxeladol: adrenergic, serotonin inhibitor &amp; opioid agonist for neurological studies.</p>

<p>Indazole-Cl is a selective ERß agonist and a selective estrogen receptor modifier (SERM).</p>

<p>ICI 199,441 hydrochloride is a potent, selective agonist of κ-opioid receptor.</p>

<p>IPAG is a potent σ-receptor antagonist (pKi=4.3). IPAG can induce cell apoptosis.</p>

<p>AZD9567: potent, selective SGRM, oral, IC50=3.8nM, effective in SCW joint inflammation.</p>

<p>AT-121 is a dual μ-opioid and neuropeptide receptor partial agonist (Kis 16.49 and 3.67 nM, respectively).</p>

<p>SSR126768A is an oxytocin receptor antagonist that inhibits uterine contractions and may be used to prevent preterm labor.</p>

<p>Apomine inhibits HMG-CoA-reductase, induces myeloma cell apoptosis, modulates myeloma, and boosts lovastatin's antitumor effects.</p>

<p>Posatirelin, a synthetic peptide, modulates and nourishes brain systems, aiding in vascular dementia research.</p>

<p>SB-657510: UT antagonist, Ki (nM) - human 61, monkey 17, cat 30, rat 65, mouse 56; reduces UII-induced inflammation, aids diabetic atherosclerosis.</p>

<p>PSB-CB5 (GPR18-IN-32)2 is a GRP18 antagonist with anti-inflammatory activity and can be used to study obesity and metabolic disorders.</p>

<p>GLPG0492 is a novel selective androgen receptor modulator.</p>

<p>Acifran (AY 25712) is an HM74A/GPR109A and GPR109B agonist and displays antihyperlipidemic activity.</p>

<p>GPR40/FFAR1 modulator 1 is a Gq-coupled free fatty acid receptor 1 (GPR40/FFAR1) agonist and allosteric modulator.</p>

<p>JNJ-20788560 is a delta opioid receptor (DOR) agonist with analgesic activity. It is more selective for DOR than for mu opioid receptors (MOR).</p>

<p>Y134, an oral estrogen receptor inhibitor, is 121x more selective for ERα (Ki=0.09 nM) over ERβ (Ki=11.31 nM), and blocks ER+ breast cancer cell growth.</p>

<p>Endoxifen HCl, a Tamoxifen metabolite, targets estrogen receptors more effectively and blocks aromatase, showing promise for breast cancer research.</p>

<p>SCH-486757 is an agonist of nociceptin-1 (NOP1) and orphanin FQ peptide receptors and is used in the study of cough.</p>

<p>P2Y2R/GPR17 antagonist 1 (Compound 14m) is a dual P2Y2R (IC50: 3.17 μM) and GPR17 (IC50: 1.67 μM) antagonist.</p>

<p>TC-MCH 7c is an oral, selectable and blood-brain barrier penetrating MCH1R antagonist with IC50 performance of 5.6 nM against hMCH1R, and TC-MCH 7c is a</p>

<p>Moveltipril (Moveltipril calcium) is a potent angiotensin-converting enzyme (ACE) inhibitor.Moveltipril is converted to captopril in the body for action.</p>

<p>μ opioid receptor agonist 1 (Compound H-1a) is an optically pure oxyheterocyclic substituted pyrroloxypyrazole derivative and an MOR receptor agonist that can</p>

<p>CL-329167, a angiotensin type 1 receptor antagonist, is used potentially for the treatment of hypertension.</p>

<p>CYT-1010, a mu-opioid receptor agonist; EC50: β-arrestin, 13.1 nM; cAMP, 0.0053 nM. Extracted from patent WO2013173730A2.</p>

<p>FK 33-824, a stable synthetic analog of methionine enkephalin, reversible with naloxone.</p>

<p>L 681176 is an inhibitor of the angiotensin-converting enzyme.</p>

<p>ADL-08-0011 is an metabolite of alvimopan.</p>

<p>JNJ-17148066 is an agonist of estrogen receptor ESR1.</p>

<p>ES 936 is a potent and selective NQO1 inhibitor, inhibiting more than 95% of NQO1 100 nM, with a cell line-dependent inhibition duration.</p>

<p>ICI 204448 is a potent and peripherally selective κ-opioid agonist.</p>

<p>Conjugated estrogens treat menopause symptoms, vaginal changes, and certain cancers.</p>

<p>Nurr1 agonist 4 (compound 8) serves as a potent Nurr1 agonist, exhibiting an EC50 value of 2.1 μM [1].</p>

<p>Halobetasol (Ulobetasol), a corticosteroid, is utilized in the research of severe localized psoriasis [1].</p>

<p>UFP-512 is a selective delta-opioid (DOP) receptor agonist.</p>

<p>Nurr1 agonist 7 is an agonist of Nurr1 (EC50: 0.12 μM), which can be used to study neurological disorders such as Parkinson's disease.</p>

<p>MB-07344 is a selective THR-β (thyroid hormone receptor β) agonist with a Ki of 2.17 nM, capable of reducing plasma total cholesterol (TPC).</p>

<p>GPR52 receptor modulator 1, a compound delineated as per Procedure 1, is a modulator of the GPR52 receptor, offering research potential in the investigation of</p>

<p>GPR139 agonist-2 (compound 20a), a potent GPR139 agonist with an EC50 of 24.7 nM, has demonstrated efficacy in rescuing social interaction deficits and</p>